Market Outlook
Global Silver
Sulfadiazine Market size is expected to increase significantly during to
forecast period (2019-2027). Burn injuries are considered severe healthcare
problems and far more serious than other epidemics such as polio. According to
the World Health Organization, around 180,000 deaths occur due to burns,
majorly in emerging economies. Furthermore, non-fatal burn injuries are the
leading cause of morbidity. This is expected to increase the demand for
anti-burn creams and lotions and subsequently drive the market growth.
Furthermore, silver sulfadiazine has been majorly used hospitals in North
America as it is considered as a powerful treatment for burns.
Silver Sulfadiazine Market –
Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
Silver sulfadiazine is
specifically used for second degree or third-degree burns on the skin, which
acts ant-bacterial drug. The World Health Organization considers silver
sulfadiazine as an Essential Medicines and is used as an antibiotic for skin
burns. Silver sulfadiazine helps to prevent growth of yeast and bacteria and is
used to treat urinary tract infections (UTI). When it is combined with
pyrimethamine, the combination is used for the treatment of toxoplasmosis.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2763
Furthermore, a typical anti burn
cream 1% of silver sulfadiazine contains, which is crucial to maintain as
excessive quantity would make it toxic. However, some organizations do not
recommend its use, as it has been a subject of research and various
speculation. Moreover, there have been some side effects of silver sulfadiazine
such as loss of appetite, dizziness, and nausea.
However, silver sulfadiazine
causes minor side effects such as nausea, loss of appetite, and dizziness,
which may hinder the demand for the product and subsequently restrain the
global silver sulfadiazine market growth. Furthermore, increasing the price of
silver, which is one of the prime raw materials for the production of silver
sulfadiazine expected to hinder
Market Regional
North America is expected to
account for the largest market share in the global silver sulfadiazine market,
during the forecast period. This is owing to increased burn cases and
increasing demand for wound-care products. According to the National Fire
Protection Association (NFPA), around every two hours, a civilian die from fire
outbreaks, which has increased the demand for wound-care products.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/silver-sulfadiazine-market-2763
Furthermore, increasing
government initiatives to fund research and development of medicines to treat
burn wounds has accelerated the market growth. Moreover, Asia Pacific is
expected to witness significant growth in the market, owing to increasing
demand for silver sulfadiazine from emerging economies such as India and China.
The countries Australia, China, and India are expected to emerge as new revenue
generators in the region.
Market Players
Key players operating in the
global silver sulfadiazine market include 3M Company, Baxter International,
Inc., Monarch Pharmaceuticals, Teva Pharmaceutical Industries Ltd, and Johnson
& Johnson Limited.
Buy-Now browse
research report: https://www.coherentmarketinsights.com/insight/buy-now/2763
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to emerging market
trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment